Evaluating Enavogliflozin for Heart and Kidney Health in Type 2 Diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of enavogliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, on cardiovascular and renal outcomes in adults with type 2 diabetes. The study is a multicenter, randomized, open-label trial comparing enavogliflozin to other established SGLT2 inhibitors like dapagliflozin and empagliflozin. A total of 2,862 participants will be enrolled, and the primary goal is to assess the time to the first occurrence of major adverse cardiovascular and renal events. This research aims to provide insights into the long-term benefits of enavogliflozin in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male and female adults aged 19 years and older at screening
2. Subjects diagnosed with T2D at screening
3. Subjects on treatment with or requiring treatment with enavogliflozin, dapagliflozin, or empagliflozin within the scope of label and reimbursement criteria

Exclusion Criteria:

1. Subjects with different types of diabetes mellitus other than T2D
2. Subjects with moderate to severe hepatic impairment
3. Subjects with contraindications to SGLT-2 inhibitors, i.e., kidney function disorders with estimated glomerular filtration (eGFR) \<60 mL/min/1.73 m2, end stage renal disease (ESRD), or on dialysis
4. Subjects with major comorbidities
5. Subjects with a history of hypersensitivity to enavogliflozin, dapagliflozin, or empagliflozin and any of its components
6. Pregnant or breastfeeding women

Where it's running

• Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea
  Seoul, South Korea Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-based prediction of five major diseases using integrated health data

  Researchers are testing an AI model to see if they can predict the onset of five major diseases in adults 30–65 by combining medical records with biospecimens and lifestyle data.

  Recruiting Asan Medical Center · Seoul, Seoul Special City · NCT07595718

• Transformative 2.0 for diabetic kidney disease

  This project will try to see if adults with diabetic kidney disease who take SGLT2 diabetes medicines have different biological patterns in archived kidney tissue than similar people who do not take these medicines.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07444203

• Early risk screening for diabetes and heart disease in Ascoli Piceno

  This project tests a new screening program for 50-year-olds in Ascoli Piceno to see if they are at risk for type 2 diabetes and cardiovascular disease.

  Recruiting at 2 sites Marche Region Regional Health Agency · Ascoli Piceno, Ascoli Piceno and 1 other locations · NCT07344701

• Vicadrostat with empagliflozin for people with type 2 diabetes, high blood pressure, and heart disease

  This trial will test whether adding vicadrostat to empagliflozin lowers cardiovascular risk in adults who have type 2 diabetes, high blood pressure, and existing cardiovascular disease but no history of heart failure.

  Recruiting at 1096 sites Phase 3 Boehringer Ingelheim · Anniston, Alabama and 1141 other locations · NCT07064473

• NightWare use for cardiovascular health in women with PTSD-related nightmares

  This study tests whether NightWare can improve heart and kidney health biomarkers in premenopausal women who have PTSD-related nightmares.

  Recruiting at 2 sites University of Colorado, Denver · Aurora, Colorado and 1 other locations · NCT07021014

• Kefir for vascular and immune health in people with or at risk for type 2 diabetes

  This 12-week test will see if drinking 350 mL of traditional kefir each day helps improve blood vessel and immune health in adults aged 24–70 who have or are at higher risk for type 2 diabetes.

  Recruiting University of Alberta · Edmonton, Alberta · NCT06695221

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.